<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02492074</url>
  </required_header>
  <id_info>
    <org_study_id>GEI-TCP I</org_study_id>
    <nct_id>NCT02492074</nct_id>
  </id_info>
  <brief_title>Gene-Environment-Interaction: Influence of the COMT Genotype on the Effects of Different Cannabinoids - a PET Study</brief_title>
  <official_title>Gene-Environment-Interaction: Influence of the COMT Genotype on the Effects of Different Cannabinoids on the Endocannabinoid System and Brain Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Central Institute of Mental Health, Mannheim</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Central Institute of Mental Health, Mannheim</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study evaluates the gene-environment interaction of the COMT-genotype on the effects of
      the phytocannabinoids delta-9-tetrahydrocannabinol, cannabidiol or a combination of both on
      induction of psychotic symptoms, endocannabinoid levels in human body fluids, neuronal
      processing, and neural oscillations. In addition the effects of the phytocannabinoids on
      lipid levels in serum and cerebrospinal fluid, cognition, neuronal processing assessed by
      fMRI as well as D2-receptor availability assessed by [18F] desmethoxyfallypride.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2019</start_date>
  <completion_date type="Anticipated">May 2020</completion_date>
  <primary_completion_date type="Anticipated">April 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Positive and Negative Syndrome Scale (total score, PANSS T) from baseline to post drug intake of both on induction of psychotic symptoms, endocannabinoid levels in human body fluids, neuronal processing, and D2-receptor availability</measure>
    <time_frame>up to 6 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in PANSS subscores and clusters (baseline to post drug intake)</measure>
    <time_frame>up to 4 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Digit Symbol Coding</measure>
    <time_frame>up to 6 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Letter-Number-Sequencing</measure>
    <time_frame>up to 6 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in emotional state (EWL, &quot;Eigenschaftsw√∂rterliste&quot;)</measure>
    <time_frame>up to 6 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in attentional state (d2-test of attention d2-R)</measure>
    <time_frame>up to 6 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in imagination (Bett's Questionaire upon Mental Imagery)</measure>
    <time_frame>up to 6 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in binocular depth inversion illusion (BDII)</measure>
    <time_frame>up to 6 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Wisconsin Card Sorting Test Performance</measure>
    <time_frame>up to 6 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of hallucinogenic states scale (APZ) (post drug intake)</measure>
    <time_frame>1 day</time_frame>
    <description>questionaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability assessments including (S)AEs, physical examination, vital signs (including heart rate and systolic and diastolic blood pressure in both supine and standing positions), and detailed laboratory assessments</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolic markers post drug intake (blood)</measure>
    <time_frame>up to 4 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolic markers post drug intake (cerebrospinal fluid)</measure>
    <time_frame>up to 4 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>D2-receptor availability post drug intake</measure>
    <time_frame>up to 5 hours</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Assessment of biomarker profiles in serum and cerebrospinal fluid of subjects</measure>
    <time_frame>1 day</time_frame>
    <description>Comparison of biomarker profiles in serum and cerebrospinal fluid after different treatments</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Healthy Volunteers</condition>
  <condition>Modeling Psychosis</condition>
  <arm_group>
    <arm_group_label>THC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects receive 20 mg delta-9-tetrahydrocannabinol (2 capsules containing 10 mg each) and corresponding cannabidiol placebo capsules.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CBD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects receive 800 mg cannabidiol (4 capsules containing 200 mg each) and corresponding delta-9-tetrahydrocannabinol placebo capsules.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CBD+THC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects receive 800 mg cannabidiol (4 capsules containing 200 mg each) and 20 mg delta-9-tetrahydrocannabinol (2 capsules containing 10 mg each)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects receive corresponding delta-9-tetrahydrocannabinol and cannabidiol placebo capsules</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Delta-9-tetrahydrocannabinol</intervention_name>
    <description>oral administration of delta-9-tetrahydrocannabinol</description>
    <arm_group_label>THC</arm_group_label>
    <arm_group_label>CBD+THC</arm_group_label>
    <other_name>Dronabinol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cannabidiol</intervention_name>
    <description>oral administration of cannabidiol</description>
    <arm_group_label>CBD</arm_group_label>
    <arm_group_label>CBD+THC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>oral administration of placebo</description>
    <arm_group_label>THC</arm_group_label>
    <arm_group_label>CBD</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed consent given by the subject

          -  Healthy young man (age between 18 and 45) insightful to the study (WST&gt; 95)

          -  Right handedness

          -  At least one time consumption of Cannabis but less than 10 times/ per lifetime, no
             consumption of other psychotropic agents (despite coffee or nicotine), no alcohol
             abuse

          -  Negative drug-screening at the time of screening

          -  Body Mass Index between 18 and 30

        Exclusion Criteria:

          -  Lack of accountability

          -  Participation in other interventional trials

          -  Severe medical or neurological illness, especially cardiovascular, renal, advanced
             respiratory, hematological or endocrinological failures or infectious diseases (acute
             hepatitis A, B or C or HIV) assessed at the time of the screening by the subject's
             history, clinical examination and laboratory testing, at the discretion of the
             investigator

          -  Any known psychiatric illness in the participant's history

          -  Known family history concerning psychiatric disorders

          -  Cannabis consumption within the last six months

          -  Consumption of any illegal drugs (except cannabis in history, see above)

          -  Intake of interfering medication, at the discretion of the investigator

          -  High intracranial pressure

          -  Any disorders in stereoscopic vision (measured by the TNO-Test, Lamerics, Utrecht) or
             hearing deficits

          -  Contraindications due to the Investigators Brochure Contraindication for Magnetic
             Resonance Imaging (e.g. cardiac pacemaker, claustrophobia, attached brace, in body
             metal, tattoos) or lumbar puncture (e.g. local or systemic infection, disturbance of
             blood coagulation, medication with anticoagulants like Phenprocoumon) or contradiction
             for the PET-CT method and the radiopharmaceutical
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>F. Markus Leweke, MD</last_name>
    <phone>+49 621 1703 2321</phone>
    <email>leweke@cimh.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Cathrin Rohleder, PhD</last_name>
    <phone>+49 621 1703 2333</phone>
    <email>rohleder@cimh.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Central Institute of Mental Health</name>
      <address>
        <city>Mannheim</city>
        <state>BW</state>
        <zip>68159</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>F. Markus Leweke, MD</last_name>
      <email>leweke@cimh.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 3, 2015</study_first_submitted>
  <study_first_submitted_qc>July 3, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 8, 2015</study_first_posted>
  <last_update_submitted>March 13, 2018</last_update_submitted>
  <last_update_submitted_qc>March 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Central Institute of Mental Health, Mannheim</investigator_affiliation>
    <investigator_full_name>F Markus Leweke</investigator_full_name>
    <investigator_title>Prof. Dr. F. Markus Leweke</investigator_title>
  </responsible_party>
  <keyword>delta-9-tetrahydrocannabinol</keyword>
  <keyword>cannabidiol</keyword>
  <keyword>COMT</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dronabinol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

